Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Saved in:
| Title: | Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. |
|---|---|
| Authors: | Shah PD; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Wethington SL; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America., Pagan C; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Latif N; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Tanyi J; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Martin LP; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Morgan M; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Burger RA; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Haggerty A; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Zarrin H; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Rodriguez D; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Domchek S; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Drapkin R; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Shih IM; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America., Smith SA; AstraZeneca, R&D Oncology, Cambridge, UK., Dean E; AstraZeneca, R&D Oncology, Cambridge, UK., Gaillard S; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America., Armstrong D; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America., Torigian DA; Department of Radiology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, United States of America., Hwang WT; Division of Biostatistics, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, United States of America., Giuntoli R; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America., Simpkins F; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America. Electronic address: Fiona.Simpkins@pennmedicine.upenn.edu. |
| Source: | Gynecologic oncology [Gynecol Oncol] 2021 Nov; Vol. 163 (2), pp. 246-253. Date of Electronic Publication: 2021 Oct 05. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34620496 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Shah+PD%22">Shah PD</searchLink>; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Wethington+SL%22">Wethington SL</searchLink>; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.<br /><searchLink fieldCode="AU" term="%22Pagan+C%22">Pagan C</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Latif+N%22">Latif N</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Tanyi+J%22">Tanyi J</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Martin+LP%22">Martin LP</searchLink>; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Morgan+M%22">Morgan M</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Burger+RA%22">Burger RA</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Haggerty+A%22">Haggerty A</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Zarrin+H%22">Zarrin H</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Rodriguez+D%22">Rodriguez D</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Domchek+S%22">Domchek S</searchLink>; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Medical Oncology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Drapkin+R%22">Drapkin R</searchLink>; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, United States of America; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Shih+IM%22">Shih IM</searchLink>; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.<br /><searchLink fieldCode="AU" term="%22Smith+SA%22">Smith SA</searchLink>; AstraZeneca, R&D Oncology, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Dean+E%22">Dean E</searchLink>; AstraZeneca, R&D Oncology, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Gaillard+S%22">Gaillard S</searchLink>; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.<br /><searchLink fieldCode="AU" term="%22Armstrong+D%22">Armstrong D</searchLink>; The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, United States of America.<br /><searchLink fieldCode="AU" term="%22Torigian+DA%22">Torigian DA</searchLink>; Department of Radiology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Hwang+WT%22">Hwang WT</searchLink>; Division of Biostatistics, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Giuntoli+R%22">Giuntoli R</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Simpkins+F%22">Simpkins F</searchLink>; Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, United States of America. Electronic address: Fiona.Simpkins@pennmedicine.upenn.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220365304%22">Gynecologic oncology</searchLink> [Gynecol Oncol] 2021 Nov; Vol. 163 (2), pp. 246-253. <i>Date of Electronic Publication: </i>2021 Oct 05. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0365304 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1095-6859 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200908258%22">00908258 </searchLink><i>NLM ISO Abbreviation: </i>Gynecol Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34620496 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ygyno.2021.08.024 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 246 Titles: – TitleFull: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Shah PD – PersonEntity: Name: NameFull: Wethington SL – PersonEntity: Name: NameFull: Pagan C – PersonEntity: Name: NameFull: Latif N – PersonEntity: Name: NameFull: Tanyi J – PersonEntity: Name: NameFull: Martin LP – PersonEntity: Name: NameFull: Morgan M – PersonEntity: Name: NameFull: Burger RA – PersonEntity: Name: NameFull: Haggerty A – PersonEntity: Name: NameFull: Zarrin H – PersonEntity: Name: NameFull: Rodriguez D – PersonEntity: Name: NameFull: Domchek S – PersonEntity: Name: NameFull: Drapkin R – PersonEntity: Name: NameFull: Shih IM – PersonEntity: Name: NameFull: Smith SA – PersonEntity: Name: NameFull: Dean E – PersonEntity: Name: NameFull: Gaillard S – PersonEntity: Name: NameFull: Armstrong D – PersonEntity: Name: NameFull: Torigian DA – PersonEntity: Name: NameFull: Hwang WT – PersonEntity: Name: NameFull: Giuntoli R – PersonEntity: Name: NameFull: Simpkins F IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2021 Nov Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1095-6859 Numbering: – Type: volume Value: 163 – Type: issue Value: 2 Titles: – TitleFull: Gynecologic oncology Type: main |
| ResultId | 1 |
